Innovus Pharmaceuticals Inc (INNV) 0.1200 $INNV
Innovus Pharma Announces Full Payment in Cash of All its Mature and Due Notes including its $384K Gemini Fund Note
ACCESSWIRE - Thu Sep 24, 10:36AM CDT
SAN DIEGO, CA / ACCESSWIRE / September 24, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTC: INNV) announced today it paid in full in cash it $384,000 note to the Gemini Fund. In addition, the Company paid in full its notes to its former Chief Financial Officer and any mature and outstanding note to Vista Capital.
Innovus Pharma Expands License and Distribution Agreement with Orimed Pharma for Androferti in Canada
ACCESSWIRE - Mon Sep 21, 5:00AM CDT
Innovus Expands its Current Agreement Eligible to Receive up to 94.55 Million Canadian Dollars in Upfront and Sales Milestone Payments plus Double-Digit Tiered Royalties
Innovus Pharma Signs Exclusive $2.6 Million Dollar Marketing and Distribution Agreement with Khandelwal Laboratories to Market and Distribute Zestra(R) EjectDelay(R) Sensum+(R) and Zestra Glide(R) for the Indian Subcontinent
ACCESSWIRE - Thu Sep 10, 11:07AM CDT
SAN DIEGO, CA / ACCESSWIRE / September 10, 2015 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma" www.innovuspharma.com (OTCQB: INNV) announced today it has entered into an exclusive marketing and distribution agreement with Khandelwal Laboratories based in India ("KLab" under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma's products including Zestra(R) to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay(R) for treating premature ejaculation, Sensum+(R) to increase penile sensitivity and Zestra Glide(R) the high viscosity water based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. This deal has been facilitated by Nortons (UK). Under the agreement, the minimum orders for the first term of the agreement are over two million and six hundred thousand ($2.6M) US dollars.
E3 Capital, LLC Initiates Coverage on Innovus Pharmaceuticals (OTCQB: INNV) With a Strong Buy Rating and a Target Price of $0.80 Per Share
ACCESSWIRE - Wed Sep 09, 7:03AM CDT
CHICAGO, IL / ACCESSWIRE / September 9, 2015 / We initiate coverage on Innovus Pharmaceuticals, Inc. ("INNV" with a strong buy rating and a price target of $0.80 per share. INNV is an emerging pharmaceutical company engaged in the commercialization, licensing, and development of nonprescription medicines and consumer care products to improve men's and women's health and vitality. The company's current product portfolio consists of Zestra(R) (for female arousal and desire), Zestra Glide(R) (female water based lubricant), EjectDelay(TM) (for premature ejaculation), and Sensum+(TM) (for reduced penile sensitivity) and FlutiCare(TM) for allergic rhinitis.
Innovus Pharmaceuticals reports first shipment of EjectDelay (Uxor) in Canada
M2 - Thu Sep 03, 7:40AM CDT
OTC health company Innovus Pharmaceuticals (OtherOTC:INNV) said on Thursday that its partner Orimed has received the first commercial shipment of EjectDelay for the Canadian market and EjectDelay will now be sold under the Uxor name in Canada.
Innovus Pharmaceuticals Announces First Commercial Shipment of EjectDelay(R) (Uxor(R)(TM)) to Canada
ACCESSWIRE - Thu Sep 03, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / September 3, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Orimed received the first commercial shipment of EjectDelay(R) sold as Uxor(TM) for the Canadian market.
Innovus Pharma Provides Update on Its Signed Commercial Partnerships for Its Products
ACCESSWIRE - Mon Aug 10, 5:01AM CDT
Innovus Announces Nine Signed Commercial Agreements in 60 Countries with Over $475 Million in Potential Sales Milestones Plus Pre-Agreed Transfer Price and/or Double Digit Royalties
Innovus Pharma Announces Closing of $500,000 Tranche of Potential $1,500,000 Financing From Institutional Investors
ACCESSWIRE - Mon Aug 03, 8:27AM CDT
SAN DIEGO, CA / ACCESSWIRE / August 3, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB: INNV) announced today it closed the first $500,000 tranche of a potential $1,500,000 financing from institutional investors.
Innovus Pharma Announces Positive Regulatory Guidance from Europe to File for Zestra(R) as Herbal Medicine
ACCESSWIRE - Thu Jul 23, 9:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / July 23, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB: INNV) announced today it received positive regulatory guidance from the European Medicines Evaluation Agency ("EMEA" through its member state Sweden to file for its product Zestra(R) as an over the counter herbal medicine. Innovus chose Sweden as the reference member state for its guidance and will be filing its marketing application in the European Union under the decentralized procedure ("DCP" for the temporary increase of arousal and desire in women with Female Sexual Interest Arousal Disorder (FSI/AD). The guidance received confirmed that Zestra(R) can be filed as a Herbal Medicine under Article 10(a) as a well-established use under Directive 2001/83/EC. The entire DCP process takes approximately 240 days. One of the major advantages of the DCP is that a company may receive identical marketing authorizations for its product in multiple- chosen European Member countries at the same time. The Company expects to file its DCP application in the Q4-2105-Q1-2016 time period.
Applied Proteomics Appoints Robert C. Verfurth as Vice President, Sales
PR Newswire - Mon Jul 20, 7:00AM CDT
Applied Proteomics Inc., a developer of protein-based molecular diagnostics, announced today the appointment of Robert C. Verfurth as the company's vice president of sales. Mr. Verfurth has more than 25 years of experience in sales leadership in the clinical laboratory, medical instrument and pharmaceutical industries, including positions with Innovus Pharmaceuticals, Inc., Apricus Biosciences, Inc., GeneOhm Sciences, Inc., BD Diagnostics, Prometheus Laboratories Inc. and Dianon Systems, Inc.
APRI: 1.65 (+0.03)
Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra(R), Zestra Glide(R), EjectDelay(R), Sensum+(R) and Vesele(R) in Turkey and Select African and Gulf Countries
ACCESSWIRE - Tue Jul 07, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / July 7, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB: INNV) announced today it has entered into an exclusive license and distribution agreement with Elis Pharmaceuticals, Ltd. ("Elis" . Pursuant to the agreement, Innovus Pharma granted to Elis an exclusive license to market and sell Innovus Pharma's products in Turkey and select African and Gulf countries. Under the agreement, Innovus Pharma is eligible to receive up to $35.5 million dollars in sales milestone payments plus an agreed-upon transfer price.
Orimed, Innovus Pharma (OTCQB: INNV) Partner, Announces the Availability of Zestra(R) and UXOR(TM) in Canadian Pharmacies in the Summer of 2015 with Over 225,000 Doses
ACCESSWIRE - Thu Jul 02, 9:00AM CDT
BOUCHERVILLE, QC / ACCESSWIRE / July 2, 2015 / Orimed Pharma announced today the availability of Zestra(R) and Uxor(TM) (sold in the US as EjectDelay(R)) for the Canadian market the summer of 2015.
Innovus Pharmaceutical Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
ACCESSWIRE - Wed Jul 01, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / July 1, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases, applauds the June 4th U. S. Food and Drug Administration's ("FDA" Advisory Committee's recommendation for the approval of flibanserinas an important step forward in women's health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder ("HSDD" , to have an approved treatment option.
Innovus Pharmaceutical's Release Results Indicating Vesele(R) Achieves 58% Increase in Sexual Desire in Women
ACCESSWIRE - Thu Jun 18, 6:02AM CDT
41% Average Increase in all Five Endpoints Evaluated
New Equity Network Radio Show Features FlutiCare(TM), Innovus Pharma's Product for Allergic Rhinitis in an Exclusive Interview with President and CEO Dr. Bassam Damaj
ACCESSWIRE - Wed Jun 10, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / June 10, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases,announced today that Dr. Bassam Damaj, President andChief Executive Officer of the Company gave an exclusive interview to Michael Yorba, the host of the show on June 5th 2015. The interview can be viewed on the following link https://www.youtube.com/watch?v=hQ9VVXt0nhw.
BUYINS.NET Issues Innovus Pharmaceuticals (INNV) SqueezeTrigger Report
M2 - Tue Jun 09, 7:19AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Innovus Pharmaceuticals (OTC: INNV) after releasing the latest short sale data through June 5, 2015. The total aggregate number of shares shorted since January 2013 is approximately 4.73 million shares. Approximately 36.01% of daily trading volume is short selling. The SqueezeTrigger price for all INNV shares shorted is $0.35. A short squeeze is expected to begin when shares of INNV close above the $0.35 SqueezeTrigger price.
Innovus Pharmaceuticals Announces Successful Top Line Results from Vesele(R) in Erectile Dysfunction Accompanying Endpoints
ACCESSWIRE - Fri Jun 05, 5:00AM CDT
Over 40% Increase in all Six Endpoints Evaluated
Innovus Pharmaceuticals Establishes over 36,000 Retail Stores as Vendors of Record for its FlutiCare(TM) Product in the US
ACCESSWIRE - Tue Jun 02, 8:01AM CDT
SAN DIEGO, CA / ACCESSWIRE / June 2, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that it has established over 36,000 retail stores as Vendors of Record for its acquired FlutiCare(TM) OTC product for Allergic Rhinitis ahead of its potential Abbreviated New Drug Application ("ANDA" approval by the Food and Drug Administration ("FDA" . The established Vendors of Record include:
Innovus Pharmaceuticals to Present at the 2015 Marcum Microcap Conference
ACCESSWIRE - Fri May 22, 10:46AM CDT
SAN DIEGO, CA / ACCESSWIRE / May 22, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCQB:INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel.
Innovus Pharmaceuticals Expands Online and Catalogue Distribution in the U.S. for its Products
ACCESSWIRE - Wed May 20, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / May 20, 2015 / Innovus Pharmaceuticals, Inc., ("InnovusPharma" or the "Company" www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that multiple new large online distributors and catalogues have begun recently to carry and order its products in the U.S.
Innovus Pharma Announces Full Payment in Cash of All its Mature and Due Notes including its $384K Gemini Fund Note
ACCESSWIRE - Thu Sep 24, 10:36AM CDT
SAN DIEGO, CA / ACCESSWIRE / September 24, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTC: INNV) announced today it paid in full in cash it $384,000 note to the Gemini Fund. In addition, the Company paid in full its notes to its former Chief Financial Officer and any mature and outstanding note to Vista Capital. Innovus Pharma Expands License and Distribution Agreement with Orimed Pharma for Androferti in Canada
ACCESSWIRE - Mon Sep 21, 5:00AM CDT
Innovus Expands its Current Agreement Eligible to Receive up to 94.55 Million Canadian Dollars in Upfront and Sales Milestone Payments plus Double-Digit Tiered Royalties
Innovus Pharma Signs Exclusive $2.6 Million Dollar Marketing and Distribution Agreement with Khandelwal Laboratories to Market and Distribute Zestra(R) EjectDelay(R) Sensum+(R) and Zestra Glide(R) for the Indian Subcontinent
ACCESSWIRE - Thu Sep 10, 11:07AM CDT
SAN DIEGO, CA / ACCESSWIRE / September 10, 2015 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
www.innovuspharma.com (OTCQB: INNV) announced today it has entered into an exclusive marketing and distribution agreement with Khandelwal Laboratories based in India ("KLab" under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma's products including Zestra(R) to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay(R) for treating premature ejaculation, Sensum+(R) to increase penile sensitivity and Zestra Glide(R) the high viscosity water based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. This deal has been facilitated by Nortons (UK). Under the agreement, the minimum orders for the first term of the agreement are over two million and six hundred thousand ($2.6M) US dollars. E3 Capital, LLC Initiates Coverage on Innovus Pharmaceuticals (OTCQB: INNV) With a Strong Buy Rating and a Target Price of $0.80 Per Share
ACCESSWIRE - Wed Sep 09, 7:03AM CDT
CHICAGO, IL / ACCESSWIRE / September 9, 2015 / We initiate coverage on Innovus Pharmaceuticals, Inc. ("INNV"
with a strong buy rating and a price target of $0.80 per share. INNV is an emerging pharmaceutical company engaged in the commercialization, licensing, and development of nonprescription medicines and consumer care products to improve men's and women's health and vitality. The company's current product portfolio consists of Zestra(R) (for female arousal and desire), Zestra Glide(R) (female water based lubricant), EjectDelay(TM) (for premature ejaculation), and Sensum+(TM) (for reduced penile sensitivity) and FlutiCare(TM) for allergic rhinitis. Innovus Pharmaceuticals reports first shipment of EjectDelay (Uxor) in Canada
M2 - Thu Sep 03, 7:40AM CDT
OTC health company Innovus Pharmaceuticals (OtherOTC:INNV) said on Thursday that its partner Orimed has received the first commercial shipment of EjectDelay for the Canadian market and EjectDelay will now be sold under the Uxor name in Canada.
Innovus Pharmaceuticals Announces First Commercial Shipment of EjectDelay(R) (Uxor(R)(TM)) to Canada
ACCESSWIRE - Thu Sep 03, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / September 3, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Orimed received the first commercial shipment of EjectDelay(R) sold as Uxor(TM) for the Canadian market. Innovus Pharma Provides Update on Its Signed Commercial Partnerships for Its Products
ACCESSWIRE - Mon Aug 10, 5:01AM CDT
Innovus Announces Nine Signed Commercial Agreements in 60 Countries with Over $475 Million in Potential Sales Milestones Plus Pre-Agreed Transfer Price and/or Double Digit Royalties
Innovus Pharma Announces Closing of $500,000 Tranche of Potential $1,500,000 Financing From Institutional Investors
ACCESSWIRE - Mon Aug 03, 8:27AM CDT
SAN DIEGO, CA / ACCESSWIRE / August 3, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB: INNV) announced today it closed the first $500,000 tranche of a potential $1,500,000 financing from institutional investors. Innovus Pharma Announces Positive Regulatory Guidance from Europe to File for Zestra(R) as Herbal Medicine
ACCESSWIRE - Thu Jul 23, 9:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / July 23, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB: INNV) announced today it received positive regulatory guidance from the European Medicines Evaluation Agency ("EMEA" through its member state Sweden to file for its product Zestra(R) as an over the counter herbal medicine. Innovus chose Sweden as the reference member state for its guidance and will be filing its marketing application in the European Union under the decentralized procedure ("DCP" for the temporary increase of arousal and desire in women with Female Sexual Interest Arousal Disorder (FSI/AD). The guidance received confirmed that Zestra(R) can be filed as a Herbal Medicine under Article 10(a) as a well-established use under Directive 2001/83/EC. The entire DCP process takes approximately 240 days. One of the major advantages of the DCP is that a company may receive identical marketing authorizations for its product in multiple- chosen European Member countries at the same time. The Company expects to file its DCP application in the Q4-2105-Q1-2016 time period. Applied Proteomics Appoints Robert C. Verfurth as Vice President, Sales
PR Newswire - Mon Jul 20, 7:00AM CDT
Applied Proteomics Inc., a developer of protein-based molecular diagnostics, announced today the appointment of Robert C. Verfurth as the company's vice president of sales. Mr. Verfurth has more than 25 years of experience in sales leadership in the clinical laboratory, medical instrument and pharmaceutical industries, including positions with Innovus Pharmaceuticals, Inc., Apricus Biosciences, Inc., GeneOhm Sciences, Inc., BD Diagnostics, Prometheus Laboratories Inc. and Dianon Systems, Inc.
APRI: 1.65 (+0.03)
Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra(R), Zestra Glide(R), EjectDelay(R), Sensum+(R) and Vesele(R) in Turkey and Select African and Gulf Countries
ACCESSWIRE - Tue Jul 07, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / July 7, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB: INNV) announced today it has entered into an exclusive license and distribution agreement with Elis Pharmaceuticals, Ltd. ("Elis" . Pursuant to the agreement, Innovus Pharma granted to Elis an exclusive license to market and sell Innovus Pharma's products in Turkey and select African and Gulf countries. Under the agreement, Innovus Pharma is eligible to receive up to $35.5 million dollars in sales milestone payments plus an agreed-upon transfer price. Orimed, Innovus Pharma (OTCQB: INNV) Partner, Announces the Availability of Zestra(R) and UXOR(TM) in Canadian Pharmacies in the Summer of 2015 with Over 225,000 Doses
ACCESSWIRE - Thu Jul 02, 9:00AM CDT
BOUCHERVILLE, QC / ACCESSWIRE / July 2, 2015 / Orimed Pharma announced today the availability of Zestra(R) and Uxor(TM) (sold in the US as EjectDelay(R)) for the Canadian market the summer of 2015.
Innovus Pharmaceutical Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
ACCESSWIRE - Wed Jul 01, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / July 1, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases, applauds the June 4th U. S. Food and Drug Administration's ("FDA" Advisory Committee's recommendation for the approval of flibanserinas an important step forward in women's health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder ("HSDD" , to have an approved treatment option. Innovus Pharmaceutical's Release Results Indicating Vesele(R) Achieves 58% Increase in Sexual Desire in Women
ACCESSWIRE - Thu Jun 18, 6:02AM CDT
41% Average Increase in all Five Endpoints Evaluated
New Equity Network Radio Show Features FlutiCare(TM), Innovus Pharma's Product for Allergic Rhinitis in an Exclusive Interview with President and CEO Dr. Bassam Damaj
ACCESSWIRE - Wed Jun 10, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / June 10, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases,announced today that Dr. Bassam Damaj, President andChief Executive Officer of the Company gave an exclusive interview to Michael Yorba, the host of the show on June 5th 2015. The interview can be viewed on the following link https://www.youtube.com/watch?v=hQ9VVXt0nhw. BUYINS.NET Issues Innovus Pharmaceuticals (INNV) SqueezeTrigger Report
M2 - Tue Jun 09, 7:19AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Innovus Pharmaceuticals (OTC: INNV) after releasing the latest short sale data through June 5, 2015. The total aggregate number of shares shorted since January 2013 is approximately 4.73 million shares. Approximately 36.01% of daily trading volume is short selling. The SqueezeTrigger price for all INNV shares shorted is $0.35. A short squeeze is expected to begin when shares of INNV close above the $0.35 SqueezeTrigger price.
Innovus Pharmaceuticals Announces Successful Top Line Results from Vesele(R) in Erectile Dysfunction Accompanying Endpoints
ACCESSWIRE - Fri Jun 05, 5:00AM CDT
Over 40% Increase in all Six Endpoints Evaluated
Innovus Pharmaceuticals Establishes over 36,000 Retail Stores as Vendors of Record for its FlutiCare(TM) Product in the US
ACCESSWIRE - Tue Jun 02, 8:01AM CDT
SAN DIEGO, CA / ACCESSWIRE / June 2, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC"
and consumer products for men's and women's health, vitality and respiratory diseases announced today that it has established over 36,000 retail stores as Vendors of Record for its acquired FlutiCare(TM) OTC product for Allergic Rhinitis ahead of its potential Abbreviated New Drug Application ("ANDA" approval by the Food and Drug Administration ("FDA" . The established Vendors of Record include: Innovus Pharmaceuticals to Present at the 2015 Marcum Microcap Conference
ACCESSWIRE - Fri May 22, 10:46AM CDT
SAN DIEGO, CA / ACCESSWIRE / May 22, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCQB:INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel. Innovus Pharmaceuticals Expands Online and Catalogue Distribution in the U.S. for its Products
ACCESSWIRE - Wed May 20, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / May 20, 2015 / Innovus Pharmaceuticals, Inc., ("InnovusPharma" or the "Company"
www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health, vitality and respiratory diseases announced today that multiple new large online distributors and catalogues have begun recently to carry and order its products in the U.S. 
